PragmatIC Semiconductor Secures $80 Million Funding
19 Oct, 2021
– NeoPhore is a Cambridge, UK-based small molecule neoantigen immuno-oncology company.
– Series B funding round closed.
– The round was led by Claris Ventures with participation from 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
– The new investment will be used to advance the company’s drug discovery pipeline.